MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington’s Disease-Related Mechanisms-Reference-Cited by-同舟云学术

MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington’s Disease-Related Mechanisms

Published:2013-01-17 Issue:1 Volume:8 Page:e54222
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Jovicic Ana,Zaldivar Jolissaint Julien Francisco,Moser Roger,Silva Santos Mariana de Fatima,Luthi-Carter Ruth

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference30 articles.

1. Huntington’s and other polyglutamine diseases: many effects of single gene mutations;R Luthi-Carter;Drug Discov Today Dis Mech,2007

2. The functions of animal microRNAs;V Ambros;Nature,2004

3. MicroRNA biogenesis: coordinated cropping and dicing;VN Kim;Nat Rev Mol Cell Biol,2005

4. Understanding microRNAs in neurodegeneration;SM Eacker;Nat Rev Neurosci,2009

5. Huntington’s disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies;JN Savas;Proc Natl Acad Sci U S A,2008

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in nanotherapeutic strategies for Huntington's disease: Design, delivery, and neuroprotective mechanisms;Coordination Chemistry Reviews;2025-01

2. Hsa_circ_0049472 contributed to amyloid-beta peptide-induced neurotoxicity, apoptosis and inflammation via regulating PI3K-AKT signaling pathway by interacting with miR-22–3p/ZNF217 axis;Brain Research Bulletin;2024-09

3. Therapeutic effects of tetrahedral framework nucleic acids and tFNAs‐miR22 on retinal ischemia/reperfusion injury;Cell Proliferation;2024-07-31

4. Small extracellular vesicles derived from microRNA-22-3p-overexpressing mesenchymal stem cells protect retinal ganglion cells by regulating MAPK pathway;Communications Biology;2024-07-03

5. Neuroinflammation and the role of epigenetic-based therapies for Huntington’s disease management: the new paradigm;Inflammopharmacology;2024-04-23